Windber, PA , January 10, 2007–ProACTive™ is primarily based on USPTO non-provisional application 10/790,404. Effective January 10, 2007 the USPTO has allowed this application and indicated that the patent will issue in three to five months. Up to six additional patent applications are planned based on prior USPTO office action restrictions on the original 10/790,404 application. We have also applied for international coverage in Australia, Canada, European Union, India, and Japan.

Jim Jordan, an executive in residence with Pittsburgh Life Sciences Greenhouse, said he has spent more than 150 hours working with Holland and McClatchey. The desire to succeed and dedication to a cause by McClatchey and Holland eventually clinched the decision to invest in ACT. “They sacrificed to a point where – I won't say they were eating bologna sandwiches and Ramen noodles – but were at a point where their families were cutting back on activities,” Jordan said. “Plus they have both had cancer in their families, which drives their desire to succeed. There are applications outside of medicine for this technology ... that are much easier to break into. But they stuck to what they feel is important – fighting cancer – and that gives you goose bumps.”

During the next several months, ACT plans to put ProACTive through rigorous testing. By year end, the company hopes to introduce the product to industry with hopes of it becoming a revenue-generating product within two years. In addition, McClatchey said ACT is involved in seeking more venture capital. The hope is to procure enough money that ACT can begin hiring staff – two to six employees – by year end. “Andy really wants to hire some people,” McClatchey said. “When you have one guy doing all of the tech work and one guy doing all of the business-related work, it gets pretty tough. “And if the funding is in place, perhaps we can increase our staff up to 10 in 2007.”